Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
Journal of Clinical Medicine · 29.09.2023 · 12 (19) · 6285
DOI: 10.3390/jcm12196285 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.09.2023. Verfasst von Monarch Shah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, University of Virginia, Charlottesville, VA 22902, USA. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nonsteroidal mineralocorticoid receptor antagonists (MRAs) present a promising therapeutic option in cardiorenal diseases, mitigating the limitations of steroidal MRAs. Finerenone, a third-generation nonsteroidal MRA, has demonstrated beneficial effects in heart failure (HF) and chronic kidney disease (CKD). Clinical trials, including FIDELIO-DKD and FIGARO-DKD, revealed finerenone’s efficacy in improving kidney and cardiovascular (CV) outcomes. Patients with CKD and type 2 diabetes (T2DM) on finerenone experienced reduced rates of cardiovascular events, including hospitalization for HF. However, these trials excluded symptomatic HF patients, focusing on asymptomatic or early-stage HF. The ongoing FINEARTS-HF trial evaluates finerenone in HF with preserved ejection fraction (HFpEF). Additionally, studies exploring finerenone and sodium-glucose cotransporter 2 (SGLT2) inhibitors’ (Empagliflozin) combination effects in CKD and T2DM (CONFIDENCE) and the selective MR modulator AZD9977 with another SGLT2 inhibitor (dapagliflozin) in HF and CKD (MIRACLE) aim to expand treatment options. While SGLT-2 inhibitors were shown to reduce hyperkalemia risk in FIDELIO-DKD and potentially lower new-onset HF incidence in FIGARO-DKD, further research is essential. So far, the evidence for the beneficial effect of finerenone in the spectrum of cardiorenal diseases is based only on the results of studies conducted in patients with T2DM, and clinical trials of finerenone in patients with nondiabetic kidney disease are ongoing. Nonsteroidal MRAs hold significant potential as pivotal treatment targets across the cardiorenal disease spectrum. This review will focus on the effects of finerenone on cardiorenal disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, University of Virginia, Charlottesville, VA 22902, USA.
- Division of Nephrology, University of Florida, Jacksonville, FL 32209, USA.
ORCID-Profile: Monarch Shah, Alaa S Awad, Emaad M Abdel-Rahman
Zitieren
APA
Shah, M., Awad, A. S., & Abdel-Rahman, E. M. (2023). Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease. Journal of Clinical Medicine, 12(19), 6285. https://doi.org/10.3390/jcm12196285
Vancouver
Shah M, Awad AS, Abdel-Rahman EM. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease. Journal of Clinical Medicine. 2023;12(19):6285. doi:10.3390/jcm12196285
BibTeX
@article{Shah2023,
author = {Shah, Monarch and Awad, Alaa S and Abdel-Rahman, Emaad M},
title = {Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {19},
pages = {6285},
doi = {10.3390/jcm12196285}
}
EUVIMED